Livagen

Origin and Structure

Livagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA), developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as a hepatic-tissue bioregulator. It sits within the Khavinson family of organ-specific short peptides, alongside Vilon (immune), Bronchogen (respiratory), and Pancragen (pancreatic), each targeting a different tissue compartment through the same general short-peptide-bioregulator mechanism.

Livagen descends from earlier bovine liver extract preparations used in Soviet hepatology. The synthetic tetrapeptide was characterized in the 1990s as what the Khavinson group identified as the minimal active core responsible for the hepatotropic effects of the crude extracts.

Proposed Mechanism

The Khavinson mechanistic model, consistent across organ-specific short peptides, proposes that Livagen enters hepatocytes, translocates to the nucleus, and binds CpG-rich regulatory regions of promoters governing hepatocyte differentiation, regenerative turnover, and cytochrome-P450-related xenobiotic metabolism. In vitro reports describe Livagen upregulating proliferative markers in cultured human hepatocytes and modulating chromatin structure in lymphocyte models — a finding that the group has extrapolated to a broader chromatin-remodeling action.

Clinical Evidence

Russian-language clinical reports on Livagen cluster around:

• Chronic hepatitis and viral hepatitis recovery. Small clinical series from the Khavinson institute and collaborating hepatology units have described normalization of ALT/AST, improved synthetic function (albumin, prothrombin), and subjective recovery markers when Livagen is added to standard care in chronic viral hepatitis populations.
• Toxic and alcoholic liver injury. Case series have reported adjunctive use in alcohol-related liver disease and chemical hepatotoxicity recovery, with improved biochemical markers over 10–20 day courses.
• Post-chemotherapy hepatic dysfunction. Oncology-rehabilitation settings have incorporated Livagen in protocols aimed at restoring hepatic function after cytotoxic regimens.
• Immune-lymphocyte effects. Separately from its hepatic positioning, some Khavinson papers describe Livagen activating chromatin in aged lymphocytes, which has driven a secondary "immune-modulating" framing.

Independent Western replication is essentially absent. The hepatology Livagen literature is almost entirely in Russian-language journals and Khavinson monographs.

Honest Evidence Assessment

Livagen occupies the standard Khavinson evidence position: a credible Russian clinical footprint in a specific indication (chronic and toxic hepatic conditions), embedded in a broader theoretical framework that has not been validated by Western molecular biology or tested in ICH-GCP-grade randomized controlled trials. For readers unfamiliar with the Russian clinical tradition, the data will feel sparse; for readers inside it, the organ-specific hepatotropic effects are well accepted within Khavinson clinics. Both readings coexist honestly.

Practical Considerations

Russian clinical use is predominantly oral encapsulated Livagen at approximately 0.3 mg/day in 10-day cycles, repeated every 3–6 months. Some protocols combine Livagen with other Khavinson peptides for broader geriatric or post-illness rehabilitation. Injectable forms from research-chemical suppliers exist but are not the primary route in the source clinical literature.

Safety and Regulatory Status

The Russian clinical literature reports no clinically significant adverse events attributable to Livagen across published series. The peptide is registered in Russia and some CIS states as a bioregulator, not as a conventional pharmaceutical. It carries no FDA, EMA, or MHRA authorization, and is not dispensed through pharmacies in Western markets. Any Western availability is via research-chemical suppliers with the usual identity and purity caveats.

Bottom Line

Livagen is the hepatic member of the Khavinson short-peptide catalogue, with a consistent Russian clinical signal in chronic hepatitis and toxic liver recovery and essentially no Western validation. It is best understood as a component of the Russian integrative-hepatology tradition rather than as an evidence-graded hepatoprotective intervention. For the most-studied Khavinson peptide, see epithalon; for aging-biomarker context, see our biological age article.